351 related articles for article (PubMed ID: 24598688)
1. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Wang M; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
[TBL] [Abstract][Full Text] [Related]
2. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Brown JR
Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
6. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
8. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Advani RH; Buggy JJ; Sharman JP; Smith SM; Boyd TE; Grant B; Kolibaba KS; Furman RR; Rodriguez S; Chang BY; Sukbuntherng J; Izumi R; Hamdy A; Hedrick E; Fowler NH
J Clin Oncol; 2013 Jan; 31(1):88-94. PubMed ID: 23045577
[TBL] [Abstract][Full Text] [Related]
9. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Brown JR
Curr Hematol Malig Rep; 2013 Mar; 8(1):1-6. PubMed ID: 23296407
[TBL] [Abstract][Full Text] [Related]
11. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Bhatt V; Alejandro L; Michael A; Ganetsky A
Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
[TBL] [Abstract][Full Text] [Related]
12. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
Spaargaren M; de Rooij MF; Kater AP; Eldering E
Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
[TBL] [Abstract][Full Text] [Related]
13. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Winer ES; Ingham RR; Castillo JJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):355-61. PubMed ID: 22300471
[TBL] [Abstract][Full Text] [Related]
14. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
16. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
17. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Davids MS; Brown JR
Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Alinari L; Quinion C; Blum KA
Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
[TBL] [Abstract][Full Text] [Related]
20. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
